Your browser doesn't support javascript.
loading
Compliance with yellow fever and measles vaccines in the revaccination program post-hematopoietic cell transplantation.
de Almeida Testa, Lucia H; Simione, Anderson J; Dos Santos, Ana Claudia F; Colturato, Iago; Barbieri, Fernanda; de Souza, Mair Pedro; Colturato, Vergilio R; Machado, Clarisse M.
Afiliação
  • de Almeida Testa LH; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
  • Simione AJ; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
  • Dos Santos ACF; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
  • Colturato I; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
  • Barbieri F; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
  • de Souza MP; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
  • Colturato VR; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
  • Machado CM; HCT Program-Amaral Carvalho Foundation, Jau, Brazil.
Transpl Infect Dis ; 25(4): e14098, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37428874
INTRODUCTION: Measles, mumps, rubella, and even poliomyelitis outbreaks have recently perplexed infectious disease clinicians and epidemiologists globally due to the decline in vaccination coverage rates in children and adults. Measles and yellow fever (YF) have represented an increasing burden on the Brazilian public health system in recent decades. Both diseases are preventable by live-attenuated viral vaccines (LAVV), which have restricted use in hematopoietic cell transplant (HCT) recipients. METHODS: Autologous and allogeneic HCT recipients returning for regular appointments at the outpatient clinic were invited to participate in the study. Patients transplanted for at least 2 years and with a printed copy of the vaccination record were included. RESULTS: We assessed the vaccination records of 273 HCT recipients after the second year of HCT (193 allogeneic and 80 autologous) and observed lower compliance with the YF vaccine (58 patients, 21.2%) than with the measles vaccine (138 patients, 50.5%, p ≤ .0001). This is the largest published series of YF vaccination in HCT recipients so far. No severe adverse events occurred. Although expected, chronic graft-versus-host disease (GVHD) did not affect the compliance with measles (p = .08) or YF vaccination (p = .7). Indeed, more allogeneic recipients received measles vaccine in comparison with autologous patients (p < .0001), suggesting that chronic GVHD was not the main reason for not being vaccinated. Children and allogeneic HCT were more likely to receive measles vaccine. Time elapsed from HCT >5 years favored both measles and YF vaccination. CONCLUSION: A better understanding of the reasons for low compliance with LAVV is necessary to overcome this problem.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Febre Amarela / Transplante de Células-Tronco Hematopoéticas / Vacina contra Febre Amarela / Sarampo Aspecto: Implementation_research Limite: Adult / Child / Humans Idioma: En Revista: Transpl Infect Dis Assunto da revista: TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Dinamarca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Febre Amarela / Transplante de Células-Tronco Hematopoéticas / Vacina contra Febre Amarela / Sarampo Aspecto: Implementation_research Limite: Adult / Child / Humans Idioma: En Revista: Transpl Infect Dis Assunto da revista: TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Dinamarca